Donna M. Wilcock - Profile and Journalist Details
Find journalists that align with your industry, location and vision. Unlock Donna M. Wilcock's full journalist profile, including location, coverage topics, current employer, biography and preferences. Sign up today and start building journalist relationships that fuel your startup's growth.
Get connected with journalists today
Donna M. Wilcock
Verified
Editor-in-Chief, Alzheimer's & Dementia
Lexington
Beats
mostly NintendoVideo games
Things I do not know or am not curious about.
Content
Acute Communication Between Microglia and Nonparenchymal Immune Cells in the Anti-Aβ Antibody-Injected Cortex
By Kate Foley, Erica M. Weekman, Donna M. Wilcock, Tiffany L. Sudduth|JNeurosciVerifiedAlzheimers diseaseamyloidantiamyloid antibodyinflammationmicrogliasingle-cell sequencingSignificance StatementAnti-Aβ monoclonal antibody therapy is the first disease-modifying therapy to be traditionally approved by the FDA. The target population is relatively small due to the incidence of adverse vascular reactions in a significant proportion of individuals.
Terminally differentiated effector memory T cells associate with cognitive and AD-related biomarkers in an aging-based community cohort
By Barbara Martin, Donna M. Wilcock, Edric D Winford, Jenny Lutshumba|bioRxivAbstractBackground and Purpose: The immune response changes during aging and the progression of Alzheimer's disease (AD) and related dementia (ADRD). Terminally differentiated effector memory T cells (called TEMRA) are important during aging and AD due to their cytotoxic phenotype and association with cognitive decline. However, it is not clear if the changes seen in TEMRAs are specific to AD-related cognitive decline specifically or are more generally correlated with cognitive decline.
Acute Communication Between Microglia and Nonparenchymal Immune Cells in the Anti-Aβ Antibody-Injected Cortex
By Kate Foley, Erica M. Weekman, Donna M. Wilcock, Tiffany L. Sudduth|JNeurosciVerifiedAlzheimers diseaseamyloidantiamyloid antibodyinflammationmicrogliasingle-cell sequencingSignificance StatementAnti-Aβ monoclonal antibody therapy is the first disease-modifying therapy to be traditionally approved by the FDA. The target population is relatively small due to the incidence of adverse vascular reactions in a significant proportion of individuals.
Company Info
Alzheimer's & Dementia
Bloomington, Indiana, United States
+1 812-855-0661